The DOI matches its Crossref record; 79 of the 83 references it cites were found in a registry or an index.
The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement
Open accessAbstract
Heterogeneity of treatment effect (HTE) refers to the nonrandom variation in the magnitude or direction of a treatment effect across levels of a covariate, as measured on a selected scale, against a clinical outcome. In randomized controlled trials (RCTs), HTE is typically examined through a subgroup analysis that contrasts effects in groups of patients defined "1 variable at a time" (for example, male vs. female or old vs. young). The authors of this statement present guidance on an alternative approach to HTE analysis, "predictive HTE analysis." The goal of predictive HTE analysis is to provide patient-centered estimates of outcome risks with versus without the intervention, taking into account all relevant patient attributes simultaneously. The PATH (Predictive Approaches to Treatment effect Heterogeneity) Statement was developed using a multidisciplinary technical expert panel, targeted literature reviews, simulations to characterize potential problems with predictive approaches, and a deliberative process engaging the expert panel. The authors distinguish 2 categories of predictive HTE approaches: a "risk-modeling" approach, wherein a multivariable model predicts the risk for an outcome and is applied to disaggregate patients within RCTs to define risk-based variation in benefit, and an "effect-modeling" approach, wherein a model is developed on RCT data by incorporating a term for treatment assignment and interactions between treatment and baseline covariates. Both approaches can be used to predict differential absolute treatment effects, the most relevant scale for clinical decision making. The authors developed 4 sets of guidance: criteria to determine when risk-modeling approaches are likely to identify clinically important HTE, methodological aspects of risk-modeling methods, considerations for translation to clinical practice, and considerations and caveats in the use of effect-modeling approaches. The PATH Statement, together with its explanation and elaboration document, may guide future analyses and reporting of RCTs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“As previously shown, the overall decline was not explained by the lifestyle coaching offered to all participants but was likely due, in part, to “exhaustion” of the population most susceptible to diabetes who developed it earlier in the study.16”
From Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial (2025) · cites this paper as [16]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evidence based medicine: what it is and what it isn't
Sackett, D. L., Rosenberg, W. M. C., Gray, J. A. M., Haynes, R. B., & Richardson, W. S. (1996) · BMJ · doi:10.1136/bmj.312.7023.71 · Cited by 15,769
Machine learning: Trends, perspectives, and prospects
Jordan, M. I., & Mitchell, T. M. (2015) · Science · doi:10.1126/science.aaa8415 · Cited by 9,955
Moons, K. G. M., Altman, D. G., Reitsma, J. B., Ioannidis, J. P. A., Macaskill, P., Steyerberg, E. W., Vickers, A. J., Ransohoff, D. F., & Collins, G. S. (2015) · Annals of Internal Medicine · doi:10.7326/m14-0698 · Cited by 5,147
Self-citationCollins, P. G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.639 · Cited by 3,315
Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015) · Annals of Internal Medicine · doi:10.7326/m14-0697 · Cited by 3,267
Consensus development methods, and their use in clinical guideline development.
Murphy, M., Black, Lamping, McKee, M., Sanderson, Askham, & Marteau (1998) · Health Technology Assessment · doi:10.3310/hta2030 · Cited by 2,076
Prognosis Research Strategy (PROGRESS) 3: Prognostic Model Research
Steyerberg, E. W., Moons, K. G. M., van der Windt, D. A., Hayden, J. A., Perel, P., Schroter, S., Riley, R. D., Hemingway, H., Altman, D. G., & for the PROGRESS Group (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001381 · Cited by 1,508 · cited 1×
“Although guidance is expanding regarding optimal approaches to prediction modeling (such as PROGRESS [Prognosis Research Strategy] [27, 28] and TRIPOD [Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis] [29]) and some guidance exists for HTE analysis (such as the Patient-C…”
MethodSelf-citationWhy Most Discovered True Associations Are Inflated
Ioannidis, J. P. A. (2008) · Epidemiology · doi:10.1097/ede.0b013e31818131e7 · Cited by 1,495
Self-citationMetalearners for estimating heterogeneous treatment effects using machine learning
Künzel, S., Sekhon, J., Bickel, P., & Yu, B. (2017) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1804597116 · Cited by 1,458
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Higgins (2002) · doi:10.1002/(issn)1097-0258 · Cited by 1,248
Subgroup analysis and other (mis)uses of baseline data in clinical trials
Assmann, S. F., Pocock, S. J., Enos, L. E., & Kasten, L. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02039-0 · Cited by 1,167
Pocock, S. J., Assmann, S. E., Enos, L. E., & Kasten, L. E. (2002) · Statistics in Medicine · doi:10.1002/sim.1296 · Cited by 1,077
Consensus development methods, and their use in clinical guideline development.
Murphy, M. P., Black, N. A., Lamping, D. L., et al. (1998) · PubMed · Cited by 965
Subgroup analysis in randomised controlled trials: importance, indications, and interpretation
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17709-5 · Cited by 942
Yeh, R. W., Secemsky, E. A., Kereiakes, D. J., Normand, S.-L. T., Gershlick, A. H., Cohen, D. J., Spertus, J. A., Steg, P. G., Cutlip, D. E., Rinaldi, M. J., et al. (2016) · JAMA · doi:10.1001/jama.2016.3775 · Cited by 934
A consumer's guide to subgroup analyses
Oxman, A. D., & Guyatt, G. H. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-1-78 · Cited by 914
Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015) · Circulation · doi:10.1161/circulationaha.114.014508 · Cited by 793
Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events
Yusuf, S., Diener, H.-C., Sacco, R. L., Cotton, D., Ôunpuu, S., Lawton, W. A., Palesch, Y., Martin, R. H., Albers, G. W., Bath, P., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804593 · Cited by 785
Subgroup analyses in randomized trials: risks of subgroup-specific analyses;
Brookes, S. T., Whitely, E., Egger, M., Smith, G. D., Mulheran, P. A., & Peters, T. J. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2003.08.009 · Cited by 775
Evidence‐Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with Averages
Kravitz, R. L., Duan, N., & Braslow, J. T. (2004) · Milbank Quarterly · doi:10.1111/j.0887-378x.2004.00327.x · Cited by 613
Brookes, S. T., Whitley, E., Peters, T. J., Mulheran, P. A., Egger, M., & Davey Smith, G. (2001) · Health Technology Assessment · doi:10.3310/hta5330 · Cited by 580
Targeting of Low-Dose CT Screening According to the Risk of Lung-Cancer Death
Kovalchik, S. A., Tammemägi, M. C., Berg, C. D., Caporaso, N. E., Riley, T. L., Korch, M., Silvestri, G. A., Chaturvedi, A. K., & Katki, H. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301851 · Cited by 570
Subgroup identification from randomized clinical trial data
Foster, J. C., Taylor, J. M. G., & Ruberg, S. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4322 · Cited by 559
How to Use a Subgroup Analysis: Users’ Guide to the Medical Literature
Sun, X., Ioannidis, J. P. A., Agoritsas, T., Alba, A. C., & Guyatt, G. (2014) · JAMA · doi:10.1001/jama.2013.285063 · Cited by 550
Self-citationPrognosis research strategy (PROGRESS) 4: Stratified medicine research
Hingorani, A. D., van der Windt, D., Riley, R. D., Abrams, K. R., Moons, K. G. M., Steyerberg, E. W., Schroter, S., Sauerbrei, W., Altman, D. G., Hemingway, H., et al. (2013) · BMJ · doi:10.1136/bmj.e5793 · Cited by 534
Self-citationPersonalized evidence based medicine: predictive approaches to heterogeneous treatment effects
Kent, D. M., Steyerberg, E. W., & Klaveren, D. V. (2018) · BMJ · doi:10.1136/bmj.k4245 · Cited by 518
Self-citationThe Challenge of Subgroup Analyses — Reporting without Distorting
Lagakos, S. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068070 · Cited by 504
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
Kent, D. M., Rothwell, P. M., Ioannidis, J. P., Altman, D. G., & Hayward, R. A. (2010) · Trials · doi:10.1186/1745-6215-11-85 · Cited by 504
Self-citationLimitations of Applying Summary Results of Clinical Trials to Individual Patients
Kent, D. M., & Hayward, R. A. (2007) · JAMA · doi:10.1001/jama.298.10.1209 · Cited by 502
Self-citationPrediction of benefit from carotid endar terectomy in individual patients: a risk-modelling study
Rothwell, P. M., & Warlow, C. P. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11415-0 · Cited by 409
A Simple Method for Estimating Interactions Between a Treatment and a Large Number of Covariates
Tian, L., Alizadeh, A. A., Gentles, A. J., & Tibshirani, R. J. (2014) · Journal of the American Statistical Association · doi:10.1080/01621459.2014.951443 · Cited by 379
Fox, K. A. A., Poole-Wilson, P. A., Clayton, T. C., Henderson, R., Shaw, T., Wheatley, D., Knight, R., & Pocock, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67222-4 · Cited by 366
When and how can real world data analyses substitute for randomized controlled trials?
Franklin, J. M., & Schneeweiss, S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.857 · Cited by 316
Can overall results of clinical trials be applied to all patients?
Rothwell, P. M. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90120-5 · Cited by 314
Three simple rules to ensure reasonably credible subgroup analyses
Burke, J. F., Sussman, J. B., Kent, D. M., & Hayward, R. A. (2015) · BMJ · doi:10.1136/bmj.h5651 · Cited by 312
Self-citationTutorial in biostatistics: data‐driven subgroup identification and analysis in clinical trials
Lipkovich, I., Dmitrienko, A., & B., R. (2017) · Statistics in Medicine · doi:10.1002/sim.7064 · Cited by 291
Self-citationFrom subgroups to individuals: general principles and the example of carotid endarterectomy
Rothwell, P. M., Mehta, Z., Howard, S. C., Gutnikov, S. A., & Warlow, C. P. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17746-0 · Cited by 281
Analysis of randomized comparative clinical trial data for personalized treatment selections
Cai, T., Tian, L., Wong, P. H., & Wei, L. J. (2010) · Biostatistics · doi:10.1093/biostatistics/kxq060 · Cited by 238
From subgroups to individuals: general principles and the example of carotid endarterectomy
Rothwell, P. M., Mehta, Z., Howard, S. P., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)70156-2 · Cited by 207
Kent, D. M., Klaveren, D. V., Paulus, J. K., D’Agostino, R. B., Goodman, S. N., Hayward, R. A., Ioannidis, J. P. A., Patrick‐Lake, B., Morton, S. C., Pencina, M. J., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3668 · Cited by 183
Self-citationKent, D. M., Nelson, J., Dahabreh, I. J., Rothwell, P. M., Altman, D. G., & Hayward, R. A. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw118 · Cited by 161
Self-citationVaradhan, R., Segal, J. B., Boyd, C. M., Wu, A. W., & Weiss, C. O. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.02.009 · Cited by 151
Self-citationSussman, J. B., Kent, D. M., Nelson, J. P., & Hayward, R. A. (2015) · BMJ · doi:10.1136/bmj.h454 · Cited by 143
Self-citationDahabreh, I. J., Hayward, R. A., & Kent, D. M. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw125 · Cited by 140
Self-citationSubgroup analyses in therapeutic cardiovascular clinical trials: Are most of them misleading?
Hernández, A. V., Boersma, E., Murray, G. D., Habbema, J. D. F., & Steyerberg, E. W. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.04.020 · Cited by 131
Self-citationIntegrating Randomized Comparative Effectiveness Research with Patient Care
Fiore, L. D., & Lavori, P. W. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510057 · Cited by 123
Researching Genetic Versus Nongenetic Determinants of Disease: A Comparison and Proposed Unification
Ioannidis, J. P. A., Loy, E. Y., Poulton, R., & Chia, K. S. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000247 · Cited by 95
Self-citationReporting Clinical Trial Results To Inform Providers, Payers, And Consumers
Hayward, R. A., Kent, D. M., Vijan, S. S., & Hofer, T. P. (2005) · Health Affairs · doi:10.1377/hlthaff.24.6.1571 · Cited by 93
Self-citationTannock, I. F. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.3-4.206 · Cited by 92
Klaveren, D. V., Balan, T. A., Steyerberg, E. W., & Kent, D. M. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.05.029 · Cited by 88
Self-citationA Historic Moment for Open Science: The Yale University Open Data Access Project and Medtronic
Krumholz, H. M., Ross, J. S., Gross, C. P., Emanuel, E. J., Hodshon, B., Ritchie, J. D., Low, J. B., & Lehman, R. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-12-201306180-00009 · Cited by 86
Self-citationVickers, A. J., & Scardino, P. T. (2009) · Trials · doi:10.1186/1745-6215-10-14 · Cited by 86
Self-citationBurke, J. F., Hayward, R. A., Nelson, J., & Kent, D. M. (2014) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000497 · Cited by 85
Self-citationProbability at the Bedside: The Knowing of Chances or the Chances of Knowing?
Goodman, S. N. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-7-199904060-00022 · Cited by 83
Self-citationSelection of thrombolytic therapy for individual patients: Development of a clinical model
Califf, R. M., Woodlief, L. H., Harrell, F. E., Lee, K. L., White, H. D., Guerci, A. D., Barbash, G. I., Simes, R. J., Weaver, W. D., Simoons, M. L., et al. (1997) · American Heart Journal · doi:10.1016/s0002-8703(97)70164-9 · Cited by 82
Basu, S., Sussman, J. B., Rigdon, J., Steimle, L., Denton, B. T., & Hayward, R. A. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002410 · Cited by 77
Self-citationSelker, H. P. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-10-199305150-00010 · Cited by 73
Self-citationCan the Learning Health Care System Be Educated With Observational Data?
Dahabreh, I. J., & Kent, D. M. (2014) · JAMA · doi:10.1001/jama.2014.4364 · Cited by 71
Self-citationKent, D. M., Hayward, R. A., Griffith, J. L., Vijan, S. S., Beshansky, J. R., Califf, R. M., & Selker, H. P. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01160-9 · Cited by 62
Self-citationSubgroups, treatment effects, and baseline risks: Some lessons from major cardiovascular trials
Parker, A. B., & Naylor, C. D. (2000) · American Heart Journal · doi:10.1067/mhj.2000.106610 · Cited by 56
The use and abuse of subgroup analysis in epidemiological research
Stallones, R. A. (1987) · Preventive Medicine · doi:10.1016/0091-7435(87)90082-x · Cited by 55
Kent, D. M., Ruthazer, R., & Selker, H. P. (2003) · Stroke · doi:10.1161/01.str.0000051506.43212.8b · Cited by 53
Self-citationKlaveren, D. V., Vergouwe, Y., Farooq, V., Serruys, P. W. J. C., & Steyerberg, E. W. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.02.012 · Cited by 51
Self-citationA PRIM approach to predictive‐signature development for patient stratification
Chen, G., Zhong, J., Belousov, A., & Devanarayan, V. (2014) · Statistics in Medicine · doi:10.1002/sim.6343 · Cited by 50
Risk Models and Patient-Centered Evidence
Shah, N. D. (2012) · JAMA · doi:10.1001/jama.2012.469 · Cited by 46
Endogenous Stratification in Randomized Experiments
Abadie, A., Chingos, M. M., & West, M. R. (2013) · National Bureau of Economic Research · doi:10.3386/w19742 · Cited by 46
Lesko, C. R., Henderson, N. C., & Varadhan, R. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2018.04.005 · Cited by 45
Self-citationCd, F., & Rp, B. (1983) · PubMed · Cited by 44
Claggett, B. L., Tian, L., Castagno, D., & Wei, L. J. (2014) · Biostatistics · doi:10.1093/biostatistics/kxu037 · Cited by 41
Ternès, N., Rotolo, F., Heinze, G., & Michiels, S. (2016) · Biometrical Journal · doi:10.1002/bimj.201500234 · Cited by 41
La, O., & McGinnis, J. M. (2010) · Cited by 37
Kovalchik, S. A., Varadhan, R., & Weiss, C. O. (2013) · Statistics in Medicine · doi:10.1002/sim.5881 · Cited by 29
Self-citationCan Knowledge About Heterogeneity in Treatment Effects Help Us Choose Wisely?
Davidoff, F. (2016) · Annals of Internal Medicine · doi:10.7326/m16-1721 · Cited by 25
van Staa, T. P., Klungel, O., & Smeeth, L. L. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12211 · Cited by 24
Stern, R. H. (2012) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2012.00592.x · Cited by 21
Decker, C., Garavalia, L. S., Garavalia, B., Gialde, E., Yeh, R. W., Spertus, J. A., & Chhatriwalla, A. K. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.03.027 · Cited by 15
Detecting treatment‐covariate interactions using permutation methods
Wang, R., Schoenfeld, D., Hoeppner, B. B., & Evins, A. E. (2015) · Statistics in Medicine · doi:10.1002/sim.6457 · Cited by 11
Prognostic Models for Older Adults
Kent, D. M. (2012) · JAMA · doi:10.1001/jama.2012.3568 · Cited by 3
Self-citation
Flagged first, then by citations
4 of the 83 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Furberg CD, 1983, Circulation, 67, I98
Cited by
Sorted by citations
Developing clinical prediction models: a step-by-step guide
Efthimiou, O., Seo, M., Chalkou, K., Debray, T., Egger, M., & Salanti, G. (2024) · BMJ · doi:10.1136/bmj-2023-078276 · Cited by 544
Preventive psychiatry: a blueprint for improving the mental health of young people
Fusar‐Poli, P., Correll, C. U., Arango, C., Berk, M., Patel, V., & Ioannidis, J. P. A. (2021) · World Psychiatry · doi:10.1002/wps.20869 · Cited by 497
Self-citationZabor, E. C., Kaizer, A. M., & Hobbs, B. P. (2020) · Chest · doi:10.1016/j.chest.2020.03.013 · Cited by 294
Kent, D. M., Saver, J. L., Kasner, S. E., Nelson, J., Carroll, J. D., Châtellier, G., Dérumeaux, G., Furlan, A. J., Herrmann, H. C., Jüni, P., et al. (2021) · JAMA · doi:10.1001/jama.2021.20956 · Cited by 256
Self-citationTakahashi, K., Serruys, P. W. J. C., Fuster, V., Farkouh, M. E., Spertus, J. A., Cohen, D. J., Park, S., Park, D., Ahn, J., Kappetein, A. P., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32114-0 · Cited by 218
Self-citation
Metadata
- Authors
- Kent, D. M., Paulus, J. K., van Klaveren, D., D'Agostino, R., Goodman, S., Hayward, R., Ioannidis, J. P. A., Patrick-Lake, B., Morton, S., Pencina, M., Raman, G., Ross, J. S., Selker, H. P., Varadhan, R., Vickers, A., Wong, J. B., & Steyerberg, E. W.
- Affiliations
- Tufts Medical Center (US)
- Erasmus Medical Center, Rotterdam, the Netherlands, and Predictive Analytics and Comparative Effectiveness (PACE) Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts (D.V.)
- Boston University, Boston, Massachusetts (R.D.)
- Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California (S.G., J.P.I.)
- University of Michigan (US)
- Stanford University (US)
- Duke Clinical Research Institute, Duke University, Durham, North Carolina (B.P., M.P.)
- Virginia Tech (US)
- Duke University (US)
- Yale University (US)
- Johns Hopkins University (US)
- Memorial Sloan Kettering Cancer Center (US)
- Leiden University Medical Center (NL)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2020-01-07
- Volume
- 172
- Issue
- 1
- Pages
- 35-45
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- PMC
- PMC7531587
- OpenAlex
- W2984947744
- Cited by
- 469
- References
- 83
- Citations by year
- 2026: 101 · 2025: 75 · 2024: 76 · 2023: 80 · 2022: 46 · 2021: 65 · 2020: 21
- FWCI
- 26.47
- Type
- journal article
- Language
- en
- Open access
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Patient-Centered Outcomes Research Institute (RR-1705-0001)
- National Cancer Institute (P30CA008748)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Keywords
- treatment effect heterogeneity, risk modeling, subgroup analysis, treatment effect modification, reporting guidelines, randomized controlled trials, clinical decision-making
- MeSH terms
- Clinical Decision-Making, Clinical Decision Rules, Humans, Individuality, Models, Statistical, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
